---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-016371"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-06-06T23:59:59+00:00"
generated_at: "2026-06-25T04:32:40.590746+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arrowhead retains three directors who failed to win majority vote at 2022 annual meeting

## Summary
- Directors Perry, Ferrari, and Waddill each received less than a majority of votes for re-election on March 17, 2022.
- The Nominating Committee and Board unanimously rejected their resignation offers, citing qualifications and board composition.
- Primary reason for vote outcome was shareholder concern over executive compensation programs.
- All three directors will continue serving until the 2023 annual meeting or until successors are elected.

## SEC filing metadata
- accession: 0001628280-22-016371
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828022016371/0001628280-22-016371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828022016371/arwr-20220601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-016371
- JSON: https://secwatch.observer/filing/0001628280-22-016371.json
- Plain text: https://secwatch.observer/filing/0001628280-22-016371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.